Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients. 

The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients. 

Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."

“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”

Sanofi will also cut the price of short-acting Apidra by 70 percent.

Share:
More In Business
Be Well: Tips to Track Your Personal Spending
Staying on top of your personal spending shouldn't be as complicated as you think. Lazetta Braxton, a certified financial planner, joined Cheddar News to provide tips on how to track that spending, such as grouping expenses into different categories.
Ready4Work Tips for Those That Have Been Laid Off
Studies show about half of Americans will experience a layoff in their lifetime. Cheddar News' Ready4Work docuseries on Thursdays at 8:30pm provides tips in its latest episode on what to do if you get that pink slip.
Load More